Comparative Pharmacology
Head-to-head clinical analysis: QLOSI versus RETEVMO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: QLOSI versus RETEVMO.
QLOSI vs RETEVMO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
QLOSI is a monoclonal antibody that binds to and inhibits the activity of interleukin-5 (IL-5), thereby reducing eosinophil production and survival.
RETEVMO (selpercatinib) is a potent and selective RET kinase inhibitor. It inhibits wild-type RET and multiple RET fusions (e.g., KIF5B-RET, CCDC6-RET) and mutations (e.g., M918T, C634W, V804M/L/E) by binding to the ATP-binding site of RET, blocking downstream signaling pathways including MAPK/ERK and PI3K/AKT, thereby inhibiting tumor cell proliferation.
100 mg orally once daily.
160 mg orally twice daily
None Documented
None Documented
Terminal elimination half-life is approximately 9 hours; clinical context: allows twice-daily dosing in patients with normal renal function.
18 hours (terminal elimination half-life) supporting twice-daily dosing; steady-state reached within ~3 days.
Primarily renal excretion of unchanged drug (approximately 85%), with the remainder eliminated via biliary/fecal routes (15%).
Primarily biliary/fecal (approximately 75% of administered dose recovered in feces as unchanged drug and metabolites); renal elimination accounts for <10% (mostly metabolites).
Category C
Category C
Kinase Inhibitor
Kinase Inhibitor